Order backlog hit 45 MSEK after new FDA guidelines, but Q1 sales fell and losses widened. A 15.2 MSEK rights issue is planned to fund commercialization, with break-even targeted at 13 MSEK annual sales.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.